{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T18:49:02Z","timestamp":1768070942818,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.atherosclerosis.2016.02.009","type":"journal-article","created":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T17:33:05Z","timestamp":1454693585000},"page":"97-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Homozygous familial hypercholesterolemia in childhood: Genotype-phenotype description, established therapies and perspectives"],"prefix":"10.1016","volume":"247","author":[{"given":"Claudia","family":"Sanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"St\u00e9phenne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Revencu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Smets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Sassolas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Di Filippo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier S.","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne M.","family":"Sokal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"45","key":"10.1016\/j.atherosclerosis.2016.02.009_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2016.02.009_bib2","series-title":"Familial Hypercholesterolemia","first-page":"2863","article-title":"The metabolic and molecular bases of inherited disease","author":"Goldstein","year":"2001"},{"issue":"32","key":"10.1016\/j.atherosclerosis.2016.02.009_bib3","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.009_bib4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.atherosclerosis.2011.06.016","article-title":"Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization","volume":"218","author":"Descamps","year":"2011","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.009_bib5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","article-title":"Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment","volume":"223","author":"Raal","year":"2012","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.02.009_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.transci.2009.05.013","article-title":"26 years of LDL-apheresis: a review of experience","volume":"41","author":"Borberg","year":"2009","journal-title":"Transfus. Apher. Sci."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.02.009_bib7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1399-3046.2007.00788.x","article-title":"Cell transplantation in the treatment of liver diseases","volume":"12","author":"Smets","year":"2008","journal-title":"Pediatr. Transpl."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.009_bib8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/00007890-199302000-00037","article-title":"Liver transplantation for familial hypercholesterolemia before the onset of cardiovascular complications","volume":"55","author":"Sokal","year":"1993","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.02.009_bib9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/MOL.0b013e328248b4ad","article-title":"Antisense apolipoprotein B therapy: where do we stand?","volume":"18","author":"Akdim","year":"2007","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2016.02.009_bib10","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/nm1195-1148","article-title":"A\u00a0pilot study of ex\u00a0vivo gene therapy for homozygous familial hypercholesterolaemia","volume":"1","author":"Grossman","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.atherosclerosis.2016.02.009_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/hum.2012.108","article-title":"Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia","volume":"24","author":"Kassim","year":"2013","journal-title":"Hum. Gene Ther."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.009_bib12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","article-title":"Molecular biology of PCSK9: its role in LDL metabolism","volume":"32","author":"Horton","year":"2007","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.atherosclerosis.2016.02.009_bib13","unstructured":"ClinicalTrials.gov identifier: NCT01624142. Trial Assessing Long Term Use of PCSK9 Inhibition in Subjects With Genetic LDL Disorders (TAUSSIG). A study to assess the long term safety and efficacy of AMG 145 on Low Density Lipoprotein-Cholesterol (LDL-C) in subjects with severe familial hypercholesterolemia. Sponsor: Amgen.http:\/\/clinicaltrials.gov\/show\/NCT01624142."},{"issue":"19","key":"10.1016\/j.atherosclerosis.2016.02.009_bib14","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.02.009_bib15","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1046\/j.1365-2362.2001.00915.x","article-title":"Impact of genetic defects on atherosclerosis in patients suspected of familial hypercholesterolaemia","volume":"31","author":"Descamps","year":"2001","journal-title":"Eur. J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.02.009_bib16","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-2275(20)40068-9","article-title":"Mutations in the low density lipoprotein receptor gene of familial hypercholesterolemic patients detected by denaturing gradient gel electrophoresis and direct sequencing","volume":"36","author":"Lombardi","year":"1995","journal-title":"J.\u00a0Lipid Res."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.02.009_bib17","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1161\/01.CIR.91.6.1641","article-title":"Genetic diagnosis with the denaturing gradient gel electrophoresis technique improves diagnostic precision in familial hypercholesterolemia","volume":"91","author":"Nissen","year":"1995","journal-title":"Circulation"},{"issue":"1\u20132","key":"10.1016\/j.atherosclerosis.2016.02.009_bib18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cccn.2005.01.028","article-title":"Identification of deletions and duplications in the low density lipoprotein receptor gene by MLPA","volume":"356","author":"Holla","year":"2005","journal-title":"Clin. Chim. Acta"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.009_bib19","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1194\/jlr.D400030-JLR200","article-title":"Multiplex ligation-dependent probe amplification of LDLR enhances molecular diagnosis of familial hypercholesterolemia","volume":"46","author":"Wang","year":"2005","journal-title":"J.\u00a0Lipid Res."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.02.009_bib20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ymgme.2007.08.120","article-title":"Anderson or chylomicron retention disease: molecular impact of five mutations in the SAR1B gene on the structure and the functionality of Sar1b protein","volume":"93","author":"Charcosset","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.02.009_bib21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1399-0004.1997.tb02478.x","article-title":"High prevalence of a novel mutation in the exon 4 of the low-density lipoprotein receptor gene causing familial hypercholesterolemia in Belgium","volume":"51","author":"Descamps","year":"1997","journal-title":"Clin. Genet."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.02.009_bib22","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/humu.1380010602","article-title":"Molecular genetics of the LDL receptor gene in familial hypercholesterolemia","volume":"1","author":"Hobbs","year":"1992","journal-title":"Hum. Mutat."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.009_bib23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1034\/j.1399-0004.2000.570205.x","article-title":"Molecular genetic testing for familial hypercholesterolemia: spectrum of LDL receptor gene mutations in The Netherlands","volume":"57","author":"Lombardi","year":"2000","journal-title":"Clin. Genet."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2016.02.009_bib24","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1161\/01.ATV.20.9.e41","article-title":"Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype","volume":"20","author":"Bertolini","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.009_bib25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/humu.20201","article-title":"LOVD: easy creation of a locus-specific sequence variation database using an \u201cLSDB-in-a-box\u201d approach","volume":"26","author":"Fokkema","year":"2005","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.atherosclerosis.2016.02.009_bib26","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.02.009_bib27","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.cjca.2013.08.003","article-title":"Incremental lowering of low-density lipoprotein cholesterol with ezetimibe 20 mg vs 10 mg daily in patients receiving concomitant statin therapy","volume":"29","author":"Ziada","year":"2013","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.02.009_bib28","first-page":"1948","volume":"115","author":"McCrindle","year":"2007","journal-title":"Drug Ther. High Risk Circ."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.02.009_bib29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2015.01.007","article-title":"Impact of LDL apheresis on aortic root atheroma in children with homozygous familial hypercholesterolemia","volume":"239","author":"Lefort","year":"2015","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.009_bib30","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.transci.2013.05.001","article-title":"Early-onset plasmapheresis and LDL-apheresis provide better disease control for pediatric homozygous familial hypercholesterolemia than HMG-CoA reductase inhibitors and ameliorate atherosclerosis","volume":"49","author":"Dann","year":"2013","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.atherosclerosis.2016.02.009_bib31","article-title":"Comparison of two low-density lipoprotein apheresis systems in patients with homozygous familial hypercholesterolemia","author":"Drouin-Chartier","year":"2015","journal-title":"J.\u00a0Clin. Apher."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.02.009_bib32","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000443139","article-title":"Long-term follow-up of a homozygous familial hypercholesterolemic patient receiving regular double filtration plasmapheresis \u2013 case report and literature review","volume":"41","author":"Tsai","year":"2016","journal-title":"Blood Purif."},{"issue":"8391","key":"10.1016\/j.atherosclerosis.2016.02.009_bib33","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/S0140-6736(84)91876-2","article-title":"Heart-liver transplantation in a patient with familial hypercholesterolemia","volume":"1","author":"Starzl","year":"1984","journal-title":"Lancet"},{"issue":"2 Pt 1","key":"10.1016\/j.atherosclerosis.2016.02.009_bib34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0022-3476(05)80531-1","article-title":"Liver transplantation in children less than 1 year of age","volume":"117","author":"Sokal","year":"1990","journal-title":"J.\u00a0Pediatr."},{"issue":"9965","key":"10.1016\/j.atherosclerosis.2016.02.009_bib35","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"9719","key":"10.1016\/j.atherosclerosis.2016.02.009_bib36","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.009_bib37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.02.009_bib38","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/01.TP.0000077420.81365.53","article-title":"Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up","volume":"76","author":"Sokal","year":"2003","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.02.009_bib39","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10545-014-9691-x","article-title":"Treating inborn errors of liver metabolism with stem cells: current clinical development","volume":"37","author":"Sokal","year":"2014","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2016.02.009_bib40","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1053\/jlts.2002.34891","article-title":"Engraftment assessment in human and mouse liver tissue after sex-mismatched liver cell transplantation by real-time quantitative PCR for Y chromosome sequences","volume":"8","author":"Wang","year":"2002","journal-title":"Liver Transpl."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2016.02.009_bib41","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3727\/096368912X659853","article-title":"Adult human liver mesenchymal stem\/progenitor cells participate to mouse liver regeneration after hepatectomy","volume":"22","author":"Khuu","year":"2013","journal-title":"Cell Transplant."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.02.009_bib42","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3748\/wjg.14.864","article-title":"Stem cells for liver tissue repair: current knowledge and perspectives","volume":"14","author":"Lysy","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2016.02.009_bib43","unstructured":"Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN). Scientific Title: A Prospective, Open Label, Multicenter, Partially Randomized, Safety Study of One Cycle of Promethera HepaStem in Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) Paediatric Patients. Primary Trial Identifying Number: NCT01765283. http:\/\/clinicaltrials.gov\/show\/NCT01765283."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016300521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016300521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T13:02:31Z","timestamp":1654261351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915016300521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":43,"alternative-id":["S0021915016300521"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.02.009","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Homozygous familial hypercholesterolemia in childhood: Genotype-phenotype description, established therapies and perspectives","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}